Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12526 - 12550 of 14373 in total
MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.
Investigational
Investigational
Investigational
SynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).
Investigational
LioCyx-M004 are autologous T cells transduced with a retroviral vector encoding a hepatitis B virus antigen-specific T cell receptor.
Investigational
BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as idecabtagene vicleucel (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for memory-like T cells.
Investigational
Investigational
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
Investigational
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Displaying drugs 12526 - 12550 of 14373 in total